Nilotinib Induced Keratosis Pilaris in a Female With Chronic Myeloid Leukemia

Ranjana Beniwal; Akriti Agrawal

doi:10.5826/dpc.1402a82

Nilotinib Induced Keratosis Pilaris in a Female With Chronic Myeloid Leukemia

Authors

Ranjana Beniwal Dr. Sampurnanand Medical College and associated group of hospitals, Jodhpur, India
Akriti Agrawal Department of Dermatology, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India

References

Jabbour E, Cortes J, Kantarjian H: Treatment selection after imatinib resistance in chronic myeloid leukemia. Target Oncol 2009;4:3–10.

Delgado L, Giraudier S, Ortonne N, Zehou O, Cordonnier C, Hulin A, Chosidow O, Tulliez M, Valeyrie-Allanore L. Adverse cutaneous reactions to the new second-generation tyrosine kinase inhibitors (dasatinib, nilotinib) in chronic myeloid leukemia. J Am Acad Dermatol. 2013;69(5):839-840.

Downloads

Published

2024-04-30

Issue

Vol. 14 No. 2 (2024): 2024 Vol 14, No 2 | April

Section

Image Letter

License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Dermatology Practical & Conceptual applies a Creative Commons Attribution License (CCAL) to all works we publish (http://creativecommons.org/licenses/by-nc/4.0/). Authors retain the copyright for their published work.

How to Cite

Nilotinib Induced Keratosis Pilaris in a Female With Chronic Myeloid Leukemia . Dermatol Pract Concept [Internet]. 2024 Apr. 30 [cited 2024 Dec. 9];14(2):e2024082. Available from: https://dpcj.org/index.php/dpc/article/view/3923